Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Rubino

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an <i>In Vitro</i> Infection ModelBrian D VanScoy, David Tenero, Simon Turner, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical StudiesMichael Trang, Julie D Seroogy, Scott A Van Wart, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 16, 2018
Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedsideCatharine C Bulik, Justin C Bader, Li Zhang, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung DiseaseChristopher M Rubino, Nikolas J Onufrak, Jakko van Ingen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 30, 2017
PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedsideCatharine C Bulik, Justin C Bader, Li Zhang, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2026
Evaluation of an <i>in vivo</i> pulmonary aspergillosis model for triazole susceptibility breakpoint developmentAlex Lepak, Sujata M Bhavnani, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Effects of Oritavancin on Coagulation Tests in the Clinical LaboratoryAdam Belley, Richard Robson, John L Francis, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniaeScott A Van Wart, Paul G Ambrose, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2007
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulationChristopher M Rubino, Lei Ma, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2007
Population pharmacokinetic model for gatifloxacin in pediatric patientsChristopher M Rubino, Edmund V Capparelli, John S Bradley, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an <i>In Vitro</i> Infection ModelBrian D VanScoy, David Tenero, Simon Turner, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical StudiesMichael Trang, Julie D Seroogy, Scott A Van Wart, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 16, 2018
Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedsideCatharine C Bulik, Justin C Bader, Li Zhang, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung DiseaseChristopher M Rubino, Nikolas J Onufrak, Jakko van Ingen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 30, 2017
PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedsideCatharine C Bulik, Justin C Bader, Li Zhang, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2026
Evaluation of an <i>in vivo</i> pulmonary aspergillosis model for triazole susceptibility breakpoint developmentAlex Lepak, Sujata M Bhavnani, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Effects of Oritavancin on Coagulation Tests in the Clinical LaboratoryAdam Belley, Richard Robson, John L Francis, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniaeScott A Van Wart, Paul G Ambrose, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2007
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulationChristopher M Rubino, Lei Ma, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2007
Population pharmacokinetic model for gatifloxacin in pediatric patientsChristopher M Rubino, Edmund V Capparelli, John S Bradley, et al.
Pageof 7